Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) announced secondary endpoint data from two Phase 3 studies of zasocitinib, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE